Cowen downgraded Jounce Therapeutics (NASDAQ: JNCE) from Outperform to Market Perform.Analyst Boris Peaker cites a lack of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Baird Remains Positive on Jounce Therapeutics (JNCE)June 4, 2018 8:08 AM Jounce Therapeutics (JNCE) PT Lowered to $10 at Wells FargoJune 4, 2018 8:02 AM Jounce Therapeutics (JNCE) Announces Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced CancersJune 4, 2018 5:58 AM JPMorgan Downgrades Jounce Therapeutics (JNCE) to NeutralJune 4, 2018 5:30 AM